Free Trial
Laura Chico

Laura Chico Analyst Performance

Managing Director, Equity Research at Wedbush

Laura Chico is a stock analyst at Wedbush focused in the medical sector, covering 38 publicly traded companies. Over the past year, Laura Chico has issued 89 stock ratings, including strong buy, buy, hold, and sell recommendations. While full access to Laura Chico's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Laura Chico's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
130 Last 8 Years
Buy Recommendations
74.62% 97 Buy Ratings
Companies Covered
38 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.8%1 ratings
Buy73.8%96 ratings
Hold20.8%27 ratings
Sell4.6%6 ratings

Out of 130 total stock ratings issued by Laura Chico at Wedbush, the majority (73.8%) have been Buy recommendations, followed by 20.8% Hold, 4.6% Sell, and 0.8% Strong Buy.

Exchange Coverage

ExchangePercentageCount
NASDAQ
89.5% of companies on NASDAQ
34 companies
NYSE
7.9% of companies on NYSE
3 companies
OTCMKTS
2.6% of companies on OTCMKTS
1 company

Laura Chico, an analyst at Wedbush, currently covers 38 companies listed on NASDAQ, NYSE and OTCMKTS, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
36 companies
94.7%
Construction
1 company
2.6%
Computer and Technology
1 company
2.6%

Laura Chico of Wedbush specializes in stock coverage within the Medical sector, with additional focus on Construction and Computer and Technology companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
29 companies
76.3%
MED - DRUGS
5 companies
13.2%
PHARMACEUTICAL PREPARATIONS
2 companies
5.3%
BLDG - RSDNT/COMR
1 company
2.6%
BUSINESS SOFTWARE SERVICES/BPO
1 company
2.6%

About Laura Chico

Laura brings more than a decade of experience in the biotechnology and drug discovery industry, as well as nine years in Equity Research. During her career, Laura has served as Vice President Equity Research at Raymond James, and as a biotech analyst in the Robert W. Baird Equity Research Healthcare group. Before entering equity research, Laura held scientific roles in both industry and academic settings with focus in central nervous system (“CNS”) diseases such as Alzheimer’s disease. Laura received her B.S. in Bacteriology from the University of Wisconsin-Madison, her M.S. in Computational Biology & Bioinformatics, and her Ph.D. in Molecular Pharmacology, from Northwestern University. She continues to serve as an adjunct assistant professor at Northwestern University’s Feinberg School of Medicine.
Follow on LinkedIn

Laura Chico's Ratings History at Wedbush

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
6/3/2026Reiterated Rating$42.94$55.00Outperform
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
6/2/2026Boost Price Target$18.59$45.00Outperform
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
6/2/2026Lower Price Target$303.77$162.00Underperform
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
6/1/2026Boost Price Target$40.26$52.00Outperform
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
5/18/2026Lower Price Target$3.58$12.00Outperform
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
5/14/2026Boost Price Target$22.94$24.00Neutral
PepGen, Inc. stock logo
PEPG
PepGen
5/13/2026Lower Price Target$1.61$4.00Outperform
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
5/13/2026Lower Price Target$7.78$16.00Outperform
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
5/11/2026Boost Price Target$25.81$34.00Outperform
Climb Bio, Inc. stock logo
CLYM
Climb Bio
5/8/2026Boost Price Target$11.94$17.00Outperform
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
5/8/2026Boost Price Target$334.73$166.00Underperform
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
5/8/2026Lower Price Target$19.89$23.00Outperform
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
5/7/2026Lower Price Target$8.66$21.00Outperform
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
5/6/2026Boost Price Target$90.24$105.00Outperform
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
5/6/2026Lower Price Target$25.01$26.00Neutral
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
5/6/2026Boost Price Target$135.06$176.00Outperform
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
5/5/2026Boost Price Target$44.91$55.00Outperform
Sionna Therapeutics, Inc. stock logo
SION
Sionna Therapeutics
5/5/2026Initiated Coverage$40.45$53.00Outperform
Sionna Therapeutics, Inc. stock logo
SION
Sionna Therapeutics
5/4/2026Upgrade$40.97Strong-Buy
Biogen Inc. stock logo
BIIB
Biogen
4/30/2026Boost Price Target$194.38$196.00Neutral
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
4/15/2026Reiterated Rating$2.96$7.00Outperform
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
4/14/2026Boost Price Target$41.18$44.00Outperform
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
4/8/2026Lower Price Target$13.96$31.00Outperform
Pharvaris N.V. stock logo
PHVS
Pharvaris
4/7/2026Boost Price Target$28.37$42.00Outperform
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
4/7/2026Boost Price Target$132.48$166.00Outperform
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
4/2/2026Lower Price Target$20.41$21.00Neutral
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
3/31/2026Lower Price Target$18.82$37.00Outperform
PepGen, Inc. stock logo
PEPG
PepGen
3/31/2026Lower Price Target$1.44$5.00Outperform
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
3/20/2026Boost Price Target$4.47$13.00Outperform
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
3/20/2026Boost Price Target$2.30$7.00Outperform
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
3/17/2026Reiterated Rating$29.78$32.00Outperform
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
3/17/2026Boost Price Target$33.96$38.00Outperform
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
3/17/2026Boost Price Target$24.27$22.00Neutral
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
3/16/2026Lower Price Target$55.23$63.00Outperform
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
3/16/2026Boost Price Target$50.21$58.00Outperform
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
3/11/2026Reiterated Rating$29.19$44.00Outperform
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
3/11/2026Reiterated Rating$8.18$14.00Outperform
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
3/10/2026Boost Price Target$62.76$64.00Outperform
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
3/10/2026Boost Price Target$79.23$80.00Outperform
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
3/9/2026Reiterated Rating$14.05$24.00Outperform
Stranded On The Flood Plains of History (Ad)

The petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed U.S. Treasury holdings by 45% from peak, and central banks are swapping dollars for gold at the fastest pace since the Cold War. Porter Stansberry believes Trump is channeling more than $3 trillion toward securing the minerals, chips, and infrastructure that make AI possible - and companies at those chokepoints like Vertiv (up 500%), GE Vernova (up 700%), and Arista Networks (up 750%) are already moving. Porter's new briefing names one asset to buy today plus five stocks positioned at the narrowest chokepoints of what he calls the Silicon Dollar.tc pixel

Read Porter's full briefing and get the ticker names today
Climb Bio, Inc. stock logo
CLYM
Climb Bio
3/5/2026Initiated Coverage$7.28$12.00Outperform
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
3/3/2026Boost Price Target$5.36$12.00Outperform
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
2/25/2026Reiterated Rating$3.69$11.00Outperform
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
2/25/2026Lower Price Target$22.13$18.00Neutral
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
2/24/2026Reiterated Rating$0.42$1.00Neutral
Ardelyx, Inc. stock logo
ARDX
Ardelyx
2/23/2026Reiterated Rating$5.73$19.00Outperform
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
2/20/2026Boost Price Target$331.61$130.00Underperform
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
2/17/2026Reiterated Rating$20.66$25.00Neutral
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
2/12/2026Boost Price Target$126.00$151.00Outperform
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
2/11/2026Boost Price Target$49.44$55.00Outperform
Biogen Inc. stock logo
BIIB
Biogen
2/9/2026Boost Price Target$201.18$187.00Neutral
Ardelyx, Inc. stock logo
ARDX
Ardelyx
1/21/2026Boost Price Target$7.76$19.00Outperform
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
1/12/2026Boost Price Target$32.85$36.00Outperform
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
1/12/2026Boost Price Target$288.45$95.00Underperform
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
12/22/2025Reiterated Rating$42.44$46.00Outperform
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
12/11/2025Boost Price Target$44.34$33.00Neutral
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
12/11/2025Lower Price Target$17.49$30.00Outperform
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
12/10/2025Boost Price Target$31.80$47.00Outperform
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
12/5/2025Boost Price Target$20.11$31.00Outperform
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
12/5/2025Reiterated Rating$189.97$83.00Underperform
Ardelyx, Inc. stock logo
ARDX
Ardelyx
11/25/2025Downgrade$5.50Hold
Pharvaris N.V. stock logo
PHVS
Pharvaris
11/13/2025Boost Price Target$26.13$30.00Outperform
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
11/7/2025Boost Price Target$29.21$36.00Outperform
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
11/7/2025Lower Price Target$17.58$32.00Outperform
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
11/6/2025Boost Price Target$33.73$46.00Outperform
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
11/6/2025Boost Price Target$164.64$77.00Underperform
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
11/5/2025Boost Price Target$21.20$32.00Outperform
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
10/15/2025Set Price Target$11.61$13.00Neutral
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
10/15/2025Downgrade$11.92$13.00Neutral
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
9/30/2025Lower Price Target$3.38$11.00Outperform
PepGen, Inc. stock logo
PEPG
PepGen
9/25/2025Boost Price Target$5.97$9.00Outperform
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
9/22/2025Reiterated Rating$146.62Outperform
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
9/12/2025Boost Price Target$37.86$44.00Outperform
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
9/9/2025Downgrade$30.18$48.00Neutral
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
8/21/2025Boost Price Target$23.72$42.00Outperform
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
8/14/2025Boost Price Target$7.03$18.00Outperform
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
8/13/2025Lower Price Target$6.15$14.00Outperform
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
8/13/2025Boost Price Target$15.66$22.00Outperform
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
8/12/2025Boost Price Target$36.10$43.00Outperform
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
8/7/2025Boost Price Target$17.24$32.00Outperform
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
8/6/2025Boost Price Target$1.97$5.00Outperform
Ardelyx, Inc. stock logo
ARDX
Ardelyx
8/5/2025Reiterated Rating$5.08$14.00Outperform
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
7/31/2025Boost Price Target$136.76$141.00Outperform
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
7/14/2025Lower Price Target$29.51$34.00Neutral
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
7/8/2025Initiated Coverage$12.12$17.00Outperform
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
6/24/2025Lower Price Target$2.76$15.00Outperform
Lennar Corporation stock logo
LEN
Lennar
6/18/2025Reiterated Rating$105.15$130.00Neutral
Biogen Inc. stock logo
BIIB
Biogen
6/12/2025Reiterated Rating$132.63$121.00Neutral
Pharvaris N.V. stock logo
PHVS
Pharvaris
6/5/2025Reiterated Rating$16.88$27.00Outperform
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
5/22/2025Downgrade$2.31$8.00Hold
Trump’s New Dollar revealed (Ad)

The last time something like this happened was 1974 - a secret deal that quietly determined the financial fate of an entire generation. According to Porter Stansberry, founder of one of the largest independent financial research firms in the world, it is happening again. Fortune calls it 'the biggest change to the world's relationship with the dollar' in a generation. Stansberry says Trump's money reset - enacted through executive orders and a treaty signed by 13 nations in December 2025 called Pax Silica - could determine whether you are enriched or quietly impoverished by the shift already underway.tc pixel

Read Porter Stansberry's full briefing and find out which moves to make now
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
5/16/2025Reiterated Rating$17.51$30.00Outperform
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
5/16/2025Reiterated Rating$1.08$4.00Outperform
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
5/15/2025Reiterated Rating$2.26$4.00Neutral
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
5/7/2025Lower Price Target$14.02$30.00Outperform
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
5/7/2025Lower Price Target$22.33$26.00Neutral
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
5/5/2025Reiterated Rating$2.85$13.00Outperform
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
5/2/2025Reiterated Rating$20.56$30.00Outperform
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
4/21/2025Reiterated Rating$13.67$43.00Outperform
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
3/14/2025Lower Price Target$2.15$13.00Outperform
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
3/14/2025Reiterated Rating$1.35$4.00Outperform
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
3/12/2025Reiterated Rating$0.49$3.00Outperform
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
3/12/2025Reiterated Rating$6.47$28.00Outperform
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
3/12/2025Reiterated Rating$22.69$36.00Outperform
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
3/6/2025Initiated Coverage$12.90$42.00Outperform
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
3/3/2025Lower Price Target$25.15$29.00Neutral
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
2/12/2025Reiterated Rating$7.24$6.00Neutral
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
2/7/2025Lower Price Target$121.12$147.00Outperform
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
1/13/2025Reiterated Rating$41.84$48.00Neutral